Fuller & Thaler Asset Management, Inc. Corcept Therapeutics Inc Transaction History

Fuller & Thaler Asset Management, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 13, 2018	SELL	$12.27 - $15.65 $5.38 Million - $6.86 Million	-438,342 Closed	0 $0
Q2 2018 Aug 07, 2018	BUY	$15.3 - $19.69 $6.71 Million - $8.63 Million	438,342 New	438,342 $6.89 Million
Q1 2018 May 14, 2018	SELL	$14.59 - $25.5 $6.42 Million - $11.2 Million	-440,300 Closed	0 $0
Q4 2017 Feb 12, 2018	BUY	$15.77 - $20.72 $4.66 Million - $6.12 Million	295,200 Added 203.45%	440,300 $7.95 Million
Q3 2017 Nov 08, 2017	BUY	$12.3 - $19.3 $1.1 Million - $1.73 Million	89,700 Added 161.91%	145,100 $2.8 Million
Q2 2017 Aug 14, 2017	BUY	N/A	55,400	55,400 $654,000

347

86.6M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $6.16B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Fuller & Thaler Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Fuller & Thaler Asset Management, Inc. with notifications on news.